EUVIMEDEUVIMED entdecken
CrossrefInfokarte

MET Expression in Upper Gastrointestinal Adenocarcinoma: Prevalence, Prognostic Impact, and Implications for Anti‐ MET Antibody‐Drug Conjugate Therapy

Tillmann Bedau, Thomas Zander, Hans Anton Schlößer, Hakan Alakus, Onur Mustafov, Reinhard Büttner, Christiane Bruns, Alexander Quaas

International Journal of Cancer · 2026-11-15 · 159 (10) · 2606-2618

DOI: 10.1002/ijc.70634 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT MET is an actionable receptor tyrosine kinase, and MET‐directed antibody–drug conjugates (ADCs) have recently entered clinical practice with FDA approval in non‐small cell lung cancer and are now being evaluated across gastrointestinal malignancies, with patient selection based on MET immunohistochemistry (IHC) 3+ membranous staining at varying percentage thresholds. However, robust real‐world data on MET protein expression and clinically relevant ADC‐aligned thresholds in upper GI adenocarcinomas remain limited. We profiled 1532 upper GI adenocarcinomas using the clinically validated VENTANA MET (SP44) IHC assay. MET was stratified by (i) 3+ membranous staining fractions (any, ≥ 10%, ≥ 50%) reflecting contemporary ADC eligibility concepts and (ii) H ‐score (0–300; high ≥ 150). Overall survival analyses and multivariable Cox regression analyses were performed. High MET expression was uncommon ( H ‐score ≥ 150: 2.3%; any 3+: 1.6%; ≥ 10% 3+: 1.3%; ≥ 50% 3+: 1.0%) and enriched in advanced T stage. MET IHC strongly predicted MET amplification ( H ‐score ≥ 150: 63.6% amplified vs. 2.4% in negatives; any 3+: 75.0% vs. 2.6%; all p < 0.001). Any MET 3+ staining was independently associated with inferior overall survival (adjusted HR 2.22, 95% CI 1.29–3.83). Most MET 3+ tumors lacked concurrent HER2 positivity, Claudin‐18.2 expression, or dMMR/MSI. In the largest real‐world cohort to date, MET overexpression identifies a rare, biologically aggressive subset with poor outcomes. By applying the latest MET‐ADC–relevant IHC criteria (including the ≥ 10% 3+ threshold), this study provides clinically translatable prevalence estimates and supports standardized MET testing to inform prospective MET‐directed ADC trials in upper GI adenocarcinoma.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →